Jonathan Isaacsohn
CEO

This biotechnology company utilizes its expertise in preclinical and clinical pharmacology, biostatistics, and regulatory affairs to expedite drug development for various diseases. By streamlining the process, it enables healthcare professionals to access essential therapies that meet significant medical needs.
Raised to date
$176MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CEO